Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894853 | 0.90 | TLR8 (0.38) | TLR7TLR8NPY5R | |
| SCHEMBL4529519 | 0.86 | NPY5R (0.47) | TLR7TLR8NPY5RACP1SLC2A1 | |
| SCHEMBL12667231 | 0.85 | TLR7 (0.42) | TLR7TLR8NPY5RSLC2A1 | |
| SCHEMBL4534637 | 0.85 | JAK1 (0.40) | NPY5RACP1JAK1JAK3NCF1 | |
| SCHEMBL12667230 | 0.77 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL1894483 | 0.76 | TGFBR1 (0.37) | TLR8JAK1JAK3TGFBR1KCNH2 | |
| SCHEMBL12667269 | 0.75 | ADORA1 (0.47) | TLR7TLR8 | |
| SCHEMBL1894485 | 0.74 | TGFBR1 (0.39) | JAK1JAK3TGFBR1KCNH2 | |
| SCHEMBL12667267 | 0.74 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL12667266 | 0.71 | TLR7 (0.46) | TLR7TLR8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943610-B2 | Pyrazolopyridine-1,4-diamines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943610-B2 | Pyrazolopyridine-1,4-diamines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1869043-A2 | PYRAZOLOPYRIDINE-1,4-DIAMINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006107853-A2 | PYRAZOLOPYRIDINE-1,4-DIAMINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124611-A1 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof | IL4, IL2, IL1A | TLR7 93/4885TLR8 256/4885NPY5R 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.